150 related articles for article (PubMed ID: 26081257)
1. Particulate cytoplasmic structures with high concentration of ubiquitin-proteasome accumulate in myeloid neoplasms.
Pecci A; Necchi V; Barozzi S; Vitali A; Boveri E; Elena C; Bernasconi P; Noris P; Solcia E
J Hematol Oncol; 2015 Jun; 8():71. PubMed ID: 26081257
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin/proteasome-rich particulate cytoplasmic structures (PaCSs) in the platelets and megakaryocytes of ANKRD26-related thrombo-cytopenia.
Necchi V; Balduini A; Noris P; Barozzi S; Sommi P; di Buduo C; Balduini CL; Solcia E; Pecci A
Thromb Haemost; 2013 Feb; 109(2):263-71. PubMed ID: 23223974
[TBL] [Abstract][Full Text] [Related]
3. Chaperone molecules concentrate together with the ubiquitin-proteasome system inside particulate cytoplasmic structures: possible role in metabolism of misfolded proteins.
Vanoli A; Necchi V; Barozzi S; Manca R; Pecci A; Solcia E
Histochem Cell Biol; 2015 Aug; 144(2):179-84. PubMed ID: 25952156
[TBL] [Abstract][Full Text] [Related]
4. Proteasome particle-rich structures are widely present in human epithelial neoplasms: correlative light, confocal and electron microscopy study.
Necchi V; Sommi P; Vanoli A; Manca R; Ricci V; Solcia E
PLoS One; 2011; 6(6):e21317. PubMed ID: 21695063
[TBL] [Abstract][Full Text] [Related]
5. PaCS is a novel cytoplasmic structure containing functional proteasome and inducible by cytokines/trophic factors.
Sommi P; Necchi V; Vitali A; Montagna D; De Luigi A; Salmona M; Ricci V; Solcia E
PLoS One; 2013; 8(12):e82560. PubMed ID: 24358206
[TBL] [Abstract][Full Text] [Related]
6. Proteasome-Rich PaCS as an Oncofetal UPS Structure Handling Cytosolic Polyubiquitinated Proteins. In Vivo Occurrence, in Vitro Induction, and Biological Role.
Solcia E; Necchi V; Sommi P; Ricci V
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30223470
[TBL] [Abstract][Full Text] [Related]
7. Polyubiquitinated proteins, proteasome, and glycogen characterize the particle-rich cytoplasmic structure (PaCS) of neoplastic and fetal cells.
Necchi V; Sommi P; Vitali A; Vanoli A; Savoia A; Ricci V; Solcia E
Histochem Cell Biol; 2014 May; 141(5):483-97. PubMed ID: 24577783
[TBL] [Abstract][Full Text] [Related]
8. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
9. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
11. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
12. Screening bone marrow samples for abnormal lymphoid populations and myelodysplasia-related features with one 10-color 14-antibody screening tube.
Rajab A; Porwit A
Cytometry B Clin Cytom; 2015; 88(4):253-60. PubMed ID: 25664445
[TBL] [Abstract][Full Text] [Related]
13. In vivo accumulation of Helicobacter pylori products, NOD1, ubiquitinated proteins and proteasome in a novel cytoplasmic structure.
Necchi V; Sommi P; Ricci V; Solcia E
PLoS One; 2010 Mar; 5(3):e9716. PubMed ID: 20300534
[TBL] [Abstract][Full Text] [Related]
14. Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN.
Mestrum SGC; de Wit NCJ; Drent RJM; Hopman AHN; Ramaekers FCS; Leers MPG
Cytometry B Clin Cytom; 2021 May; 100(3):322-330. PubMed ID: 32857909
[TBL] [Abstract][Full Text] [Related]
15. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms.
Vardiman JW
Chem Biol Interact; 2010 Mar; 184(1-2):16-20. PubMed ID: 19857474
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
[TBL] [Abstract][Full Text] [Related]
17. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
18. Immunophenotypic features of granulocytes, monocytes, and blasts in myelodysplastic syndromes.
Moon HW; Huh JW; Lee M; Hong KS; Chung WS
Korean J Lab Med; 2010 Apr; 30(2):97-104. PubMed ID: 20445324
[TBL] [Abstract][Full Text] [Related]
19. The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders.
Del Cañizo MC; Brufau A; Mota A; Lopez N; Fernandez ME; Vallejo C; Hernandez JM; Garcia JL; San Miguel JF
Haematologica; 1998 Jan; 83(1):3-7. PubMed ID: 9580461
[TBL] [Abstract][Full Text] [Related]
20. Analysis of myeloid and lymphoid markers on the surface and in the cytoplasm of mononuclear bone marrow cells in patients with myelodysplastic syndrome.
Schlesinger M; Silverman LR; Jiang JD; Yagi MJ; Holland JF; Bekesi JG
J Clin Lab Immunol; 1996; 48(4):149-66. PubMed ID: 9819667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
